Abstract
Purpose of review
This review seeks to establish the role of beta-blockers (B-adrenergic receptor antagonists) in the pathophysiology of migraine prophylaxis, compare the efficacy of this group of medications with other common prophylactic agents, and also explore the relative benefits of using individual beta-blockers compared with others.
Recent findings
New evidence supports beta-blockers having several mechanisms of action in migraine prophylaxis. Numerous trials reveal significant clinical differences between various beta-blockers in migraine prophylaxis and that commonly used doses of beta-blockers are not optimal. There are also updated guidelines regarding beta-blocker use in migraine prophylaxis.
Summary
Beta-blockers appear to have several mechanisms of action in migraine prophylaxis. We found extensive evidence supporting beta-blockers being effective in migraine prophylaxis. These are often not used at optimum doses; however, when they are, they compare generally favorably compared with other classes of medications. More recent evidence appears to show a relatively favorable side effect profile of beta-blockers compared with previous reports (Barron et al. IJC 163:3572–3579, 2013).
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Koehler PJ, Tfelt Hansen PC. History of methysergide. Cephalalgia. 2008;N28(11):1126–35.
Rabkin R, Stables D, Levin N, et al. The prophylactic value of propranolol in angina pectoris. Am J Cardiol. 1966;18:370–83.
Prichard BNC. Hypotensive action of pronethalol. Br Med J. 1964;1:1227–8.
Quirke V. Putting theory into practice: James black, receptor theory and the development of the beta-blockers at ICI, 1958–1978. Med Hist. 2006;50:69–92.
• Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018;15:313–23 A recent and comprehensive review of prophylactic migraine medications and their possible mechanism of action related to migraine pathophysiology.
Hieble JP. Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics. Pharm Acta Helv. 2000;74:163–71.
Schoenen J, Ambrosini A, Sandor PS, et al. Evoked potentials and transcranial magnetic stimulation in migraine: published data and viewpoint on their pathophysiologic significance. Clin Neurophysiol. 2003;114:955–72.
Nyrke T, Kangasniemi P, Lang AH, Petersen E. Steady-state visual evoked potentials during migraine prophylaxis by propranolol and femoxetine. Acta Neurol Scand. 1984;69:9–14.
Gehrwig M, Niehaus L, Stude P, et al. Beta-blocker migraine prophylaxis affects the excitability of the visual cortex as revealed by transcranial magnetic stimulation. J Headache Pain. 2012;13:83–9.
•• Jackson J, Cogbill E, Santana-Davila R, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One. 2015;10:7 A very comprehensive systematic meta-analysis of historical and more recent publications observing the efficacy of common prophylactic migraine medications. Includes publications comparing different medications with each other.
Diener HC, Scholz E, Dichgans J, Gerber WD, Jäck A, Bille A, et al. Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potential. Ann Neurol. 1989;25:125–30.
Maertens de Noordhout A, Timsit-Berthier M, Timsit M, et al. Effects of beta blockade on contingent negative variation in migraine. Ann Neurol. 1987;21:111–2.
Siniatchkin M, Andrasik F, Kropp P, Niederberger U, Strenge H, Averkina N, et al. Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo- controlled study. Cephalalgia. 2007;27:1024–32.
Schoenen J, Maertens de Noordhout A, Timsit-Berthier M, et al. Contingent negative variation and efficacy of beta-blocking agents in migraine. Cephalalgia. 1986;6:229–33.
Sandor PS, Afra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache. 2000;40:30–5.
Coppola G, Iacovelli E, Bracaglia M, Serrao M, di Lorenzo C, Pierelli F. Electrophysiological correlates of episodic migraine chronification: evidence for thalamic involvement. J Headache Pain. 2013;14:76.
Coppola G, Tinelli E, Lepre C, Iacovelli E, di Lorenzo C, di Lorenzo G, et al. Dynamic changes in thalamic microstructure of migraine without aura patients: a diffusion tensor magnetic resonance imaging study. Eur J Neurol. 2014;21:287–e13.
Shields KG, Goadsby PJ. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2005;128:86–97.
Johnson KW, Phebus LA, Cohen ML. Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res. 1998;51:219–44.
Longmore J, Maguire JJ, Macleod A, et al. Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D receptor agonist sumatriptan and 5-HT in human isolated coronary artery. Br J Clin Pharmacol. 2000;49:126–31.
Cruickshank JM, Prichard BNC. Beta-blockers in clinical practice. 1st ed. London: Churchill Livingstone; 1988. p. 177–274.
Ashina M, Bendtsen L, Jensen R, et al. Nitric oxide-induced headache in patients with chronic tension-type headache. Brain. 2000;123:1830–7.
• Hebestreit J, May A. The enigma of site of action of migraine preventives: no effect of metoprolol on trigeminal pain processing in patients and healthy controls. J Headache Pain. 2017;18:116 A study using fMRI that appears to suggest that the mechanism of action of metoprolol may be peripheral rather than central. The study has some weaknesses; it only observed subjects after 3 months of starting metoprolol, the dose of metoprolol was relatively low at 75mg daily, and it had a small sample size of 45 subjects. However, it still raises some questions as to our current understanding of the mechanism of action of beta-blockers in migraine.
Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52:930–45.
Pringsheim T, Davenport W, Mackie G, et al. Canadian headache society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39:1–59.
Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009;16:968–81.
•• Tfelt-Hansen P, Agesen FN, Furberg N. Pharmacokinetic variability of drugs used for the prophylactic treatment of migraine. CNS Drugs. 2017;31:389–403 Review evaluating the variability in pharmacokinetics amongst prophylactic migraine medications. Highlights the importance of personalized medicine when choosing treatment options in migraineurs.
Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;2:CD003225.
Carroll JD, Reidy M, Savundra PA, Cleave N, McAinsh J. Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses. Cephalalgia. 1990;10:101–5.
Al-Qassab HK, Findler LJ. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo-controlled study. Cephalalgia. 1993;13:128–31.
Gerber WD, Diener HC, Scholz E, Niederberger U. Responder and non-responder to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis. Cephalalgia. 1991;11:37–45.
Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994;44:647–51.
Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand. 2008;118:301–5.
Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2014;251:943–50.
Yadav R, Shukla SK. Propranolol versus topiramate in prophylaxis of migraines among children and adolescents: a randomized, double-blind clinical trial. International Journal of Research in Medical Sciences. 2017;5:4307–11.
Tonekaboni SH, Ghazavi A, Fayyazi A, et al. Prophylaxis of childhood migraine: topiramate versus propranolol. Iran J Child Neuro. 2013;7:9–14.
Olsson JE, Behring JC, Forssman B. Metoprolol and propranolol in migraine prophylaxis: a double-blind multicentre study. Acta Neurol Scand. 1984;70:160–8.
Tfelt-Hansen P. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand. 1984;69:1–8.
Hedman C, Andersen AR, Andersson PG, Gilhus NE, Kangasniemi P, Olsson JE, et al. Symptoms of classic migraine attacks: modifications brought on by metoprolol. Cephalalgia. 1988;8:279–84.
Langoht HD, Gerber WD, Koletzki D, et al. Clomipramine and metoprolol in migraine prophylaxis- a double- blind crossover study. Headache. 1985;25:107–13.
Steiner TJ, Joesph R, Hedman C, et al. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache. 1998;28:15–23.
Stellar S, Ahrens SP, Meibohm MR, et al. Migraine prevention with timolol. A double-blind crossover study. JAMA. 1984;252:2576–80.
Standnes B. The prophylactic effect of timolol versus propranolol and placebo in common migraine: beta-blockers in migraine. Cephalalgia. 1982;2:165–70.
Freitag FG, Diamond S. Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Am Osteopath Assoc. 1984;84:343–7.
Kostis JB, Rosen RC. Central nervous system effect of beta-adrenergic- blocking drugs: the role of ancillary properties. Circulation. 1987;1:204–12.
Sudilovsky A, Elkind AH, Ryan RE Sr, et al. Comparative efficacy of nadolol and propranolol in the management of migraine. Headache. 1987;27:421–6.
Ryan RE Sr, Ryan RE Jr, Sudilovsky A. Nadolol: its use in the prophylactic treatment of migraine. Headache. 1983;23:26–31.
Olerud B, Gustavsson CL, Furberg B. Nadolol and propranolol in migraine management. Headache. 1986;26:490–3.
Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349.
Ko DT, Hebert PR, Coffee CS, et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med. 2004;164:1389–94.
• Lu H, Kam J, Nordin RB, et al. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. J Geriatr Cardiol. 2016;13:749–59 Demonstrates significant risk of symptomatic bradyarrhythmias in older patients. This is important since many patients within this age group (over 64) are currently on beta-blockers for migraine prophylaxis and this risk factor is often not considered.
Frishman WH. Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity. N Engl J Med. 1983;308:940–4.
Dickstein K, Cohen-Solal A, Filippatos G, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442.
Dunlop D, Shanks RG. Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother. 1968;32:201–18.
Khosla S, Kunjummen B, Khaleel R. Safety of therapeutic beta-blockade in patients with coexisting bronchospastic airway disease and coronary artery disease. Am J Ther. 2003;10:48–50.
Frohlich ED, Tarazi RC, Dustan HP. Peripheral arterial insufficiency. A complication of beta-adrenergic blocking therapy. JAMA. 1969;208:2471–2.
Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151:1769.
Thadani U, Whitsett TL. Beta-adrenergic blockers and intermittent claudication. Time for reappraisal. Arch Intern Med. 1991;151:1705–7.
Heintzen MP, Strauer BE. Peripheral vascular effects of beta-blockers. Eur Heart J. 1994;15:2–7.
Ko DT, Hebert PR, Coffee CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–7.
Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24:1928–3192.
Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001;37:250–4.
Abramson EA, Arky RA, Woeber KA. Effects of propranolol on the hormonal and metabolic responses to insulin-induced hypoglycaemia. Lancet. 1996;24:21386–8.
Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA. 1997;278:40–3.
Deacon SP, Barnett D. Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. Br Med J. 1976;2:272–3.
Mills GA, Horn JR. Beta-blockers and glucose control. Drug Intell Clin Pharm. 1985;19:246–51.
Tfelt-Hansen P. The headaches: β-adrenoceptor blocking drugs in migraine prophylaxis. In: Olesen J, Goadsby P, Ramadan M, et al., editors. The Headaches. 3rd ed. Philadelphia: Lipincott, Williams & Wilkins; 2006.
Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a β-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003;23:961–2.
Pasqual J, Rivas MT, Leira R. Testing the combination beta-blockers plus topiramate in refractory migraine. Acta Neuro Scand. 2007;115:81–3.
Silberstein SD, Dodick DW, Lindblad AS, Holroyd K, Harrington M, Mathew NT, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78:976–84.
Rao BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India. 2000;48:223–6.
Domingues RB, Silva AL, Domingues SA, et al. A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. Arq Neuropsiquiatr. 2009;67:973–7.
Bordini CA, Arruda MA, Ciciarelli MC, Speciali JG. Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial. Arq Neuropsiaquiatr. 1997;55:536–41.
Yancey JR, Sheridan R, Koren KG. Chronic daily headache: diagnosis and management. Am Fam Physician. 2014;89:642–8.
Palferman TG, Gibberd FB, Simmonds JP. Prophylactic propranolol in the treatment of headache. Br J Clin Pract. 1993;37:28–9.
Dodick DW. Chronic daily headaches. N Engl J Med. 2006;354:158–65.
Barron AJ, Zaman N, Cole G, et al. Systematic review of genuine versus spurious side-effects of bets-blockers in heart failure using placebo control. Recommendations for patient information. Int J Cardiol. 2013;163:3572–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Headache
Rights and permissions
About this article
Cite this article
Danesh, A., Gottschalk, P.C.H. Beta-Blockers for Migraine Prevention: a Review Article. Curr Treat Options Neurol 21, 20 (2019). https://doi.org/10.1007/s11940-019-0556-3
Published:
DOI: https://doi.org/10.1007/s11940-019-0556-3